Serial 88880733
Live / Registered — Registered (as of 31 May 2022)
What this means for you
Registered since 31 May 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88880733
- Registration number
- 6741952
- Mark type
- Design / logo
- Filed
- 21 Apr 2020
- Published for opposition
- 02 Nov 2021
- Registered
- 31 May 2022
- Attorney of record
- Danielle I. Mattessich
Goods and services
- Class 005 — Pharmaceuticals: Cells for medical use; Stem cells for medical use; Pharmaceutical preparations containing cells for the treatment of hypoxic-ischemic encephalopathy, epidermolysis bullosa, cerebral infarction, stroke apoplexia cerebri, acute myocardial infarction, spinal cord injuries, amyotrophic lateral sclerosis (ALS), interstitial cystitis, acute respiratory distress syndrome (ARDS), peripheral arterial disease (PAD) and neonatal chronic lung disease (CLD); Pharmaceutical preparations containing stem cells for the treatment of hypoxic-ischemic encephalopathy, epidermolysis bullosa, cerebral infarction, stroke apoplexia cerebri, acute myocardial infarction, spinal cord injuries, amyotrophic lateral sclerosis (ALS), interstitial cystitis, acute respiratory distress syndrome (ARDS), peripheral arterial disease (PAD) and neonatal chronic lung disease (CLD); Pharmaceutical composition containing cells for the treatment of hypoxic-ischemic encephalopathy, epidermolysis bullosa, cerebral infarction, stroke apoplexia cerebri, acute myocardial infarction, spinal cord injuries, amyotrophic lateral sclerosis (ALS), interstitial cystitis, acute respiratory distress syndrome (ARDS), peripheral arterial disease (PAD) and neonatal chronic lung disease (CLD); Pharmaceutical composition containing stem cells for the treatment of hypoxic-ischemic encephalopathy, epidermolysis bullosa, cerebral infarction, stroke apoplexia cerebri, acute myocardial infarction,spinal cord injuries, amyotrophic lateral sclerosis (ALS), interstitial cystitis, acute respiratory distress syndrome (ARDS), peripheral arterial disease (PAD) and neonatal chronic lung disease (CLD)
Owner
- Life Science Institute, Inc., Tokyo, JP
- Life Science Institute, Inc., Tokyo, JP
- Life Science Institute, Inc., Tokyo, JP
Prosecution history
- 31 May 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 31 May 2022 — REGISTERED-PRINCIPAL REGISTER
- 26 Apr 2022 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 15 Mar 2022 — NOTICE OF ALLOWANCE CANCELLED
- 26 Apr 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 15 Mar 2022 — TEAS DELETE 1(B) BASIS RECEIVED
- 28 Dec 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Nov 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Nov 2021 — PUBLISHED FOR OPPOSITION
- 13 Oct 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 28 Sept 2021 — ELECTRONIC RECORD REVIEW COMPLETE
- 24 Sept 2021 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 20 Sept 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Sept 2021 — EXAMINER'S AMENDMENT ENTERED
- 20 Sept 2021 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED